INZ 701

Drug Profile

INZ 701

Alternative Names: INZ-701

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inozyme Pharma
  • Class Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Calcinosis

Most Recent Events

  • 15 Nov 2017 Preclinical trials in Calcinosis in USA before November 2017 , Inozyme Pharma website - Nov 2017)
  • 15 Nov 2017 Inozyme Pharma plans a phase I trial for Generalised arterial calcification of infancy (Inozyme Pharma website; 9227398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top